Phocas Financial Corp. Has $418,000 Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Phocas Financial Corp. lessened its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 85.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,528 shares of the company’s stock after selling 195,023 shares during the period. Phocas Financial Corp.’s holdings in Elanco Animal Health were worth $418,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Commerce Bank lifted its holdings in Elanco Animal Health by 2.2% in the third quarter. Commerce Bank now owns 35,114 shares of the company’s stock valued at $516,000 after buying an additional 741 shares during the period. MTM Investment Management LLC lifted its holdings in Elanco Animal Health by 9.3% in the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock valued at $172,000 after buying an additional 1,200 shares during the period. M&T Bank Corp lifted its holdings in Elanco Animal Health by 5.9% in the third quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock valued at $388,000 after buying an additional 1,464 shares during the period. Venturi Wealth Management LLC lifted its holdings in Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after buying an additional 1,601 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its holdings in Elanco Animal Health by 1.4% in the third quarter. Parkman Healthcare Partners LLC now owns 127,812 shares of the company’s stock valued at $1,878,000 after buying an additional 1,770 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday. Leerink Partners began coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and a consensus target price of $15.57.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $11.15 on Thursday. Elanco Animal Health Incorporated has a 1 year low of $10.20 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market capitalization of $5.51 billion, a PE ratio of 27.88, a P/E/G ratio of 2.50 and a beta of 1.42. The company’s 50 day simple moving average is $11.74 and its two-hundred day simple moving average is $13.06.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.08 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.